Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flows from operating activities
Net loss	$ (26,908)	$ (10,612)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense	221	501
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan	949	743
Stock-based compensation - PAVmed Inc. 2014 Equity Plan	81	189
Change in fair value - Senior Secured Convertible Note	14,478	(291)
Debt extinguishment loss - Senior Secured Convertible Note		167
Amortization of common stock payment for vendor service agreement	74	23
Changes in operating assets and liabilities:
Accounts receivable	(16)	(4)
Prepaid expenses and other current assets	(185)	345
Accounts payable	(412)	(176)
Accrued expenses and other current liabilities	(756)	(704)
Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee	9	(2,793)
Net cash flows used in operating activities	(12,465)	(12,612)
Cash flows from investing activities
Purchase of equipment	(93)	(37)
Net cash flows used in investing activities	(93)	(37)
Cash flows from financing activities
Proceeds – issue of preferred stock		18,165
Proceeds – issue of common stock - Registered Direct Offering, net of fees	14,934
Proceeds – issue of Senior Secured Convertible Notes	360
Proceeds – exercise of stock options	3	4
Proceeds – issue common stock – Employee Stock Purchase Plan	141	353
Net cash flows provided by financing activities	15,438	18,522
Net increase (decrease) in cash	2,880	5,873
Cash, beginning of period	22,358	18,896
Cash, end of period	$ 25,238	$ 24,769